| Base-case values | Range |  | |||
---|---|---|---|---|---|---|
Capecitabine | Observation | Lower | Upper | Rule | Distributionc | |
Capecitabine for the first year ($/month) | 306.48 | 0 | 26.84 | 306.48 | Rangea | Gamma |
Monitoring safety of capecitabine therapy in the first year ($/month) | 46.83 | 0 | 37.46 | 56.20 |  ± 20% | Gamma |
Treatment after relapse ($/month)b | 1546.43 | 0 | 773.22 | 2319.65 |  ± 50% | Gamma |
Routine follow-up ($/month) | Â | |||||
  < 3 years | 38.39 | 30.71 | 46.07 |  ± 20% | Gamma | |
 3–5 years | 21.32 | 17.06 | 25.58 |  ± 20% | Gamma | |
  > 5 years | 12.78 | 10.22 | 15.34 |  ± 20% | Gamma | |
Time cost ($/month) | Â | |||||
  < 1 year | 49.97 | 16.66 | 39.97 (capecitabine) 13.33 (observation) | 59.96 (capecitabine) 19.99 (observation) |  ± 20% | Gamma |
 1–2 years | 16.66 | 13.33 | 19.99 |  ± 20% | Gamma | |
 3–5 years | 8.33 | 6.66 | 10.0 |  ± 20% | Gamma | |
  > 5 years | 4.16 | 3.33 | 4.99 |  ± 20% | Gamma | |
Travel cost ($/month) | Â | |||||
  < 1 year | 12.37 | 4.12 | 9.90 (capecitabine) 3.30 (observation) | 14.84 (capecitabine) 4.94 (observation) |  ± 20% | Gamma |
 1–2 years | 4.12 | 3.30 | 4.94 |  ± 20% | Gamma | |
 3–5 years | 2.06 | 1.65 | 2.47 |  ± 20% | Gamma | |
  > 5 years | 1.03 | 0.82 | 1.24 |  ± 20% | Gamma | |
Management of grade 3/4 adverse events ($/case) | Â | |||||
 Hand-foot syndrome | 15.46 | - | 12.37 | 18.55 |  ± 20% | Gamma |
 Diarrhea | 44.30 | - | 28.50 | 54.60 | [45] | Gamma |
Incidence rate of grade 3/4 adverse events, % | Â | |||||
 Hand-foot syndrome | 13.45 | 0 | 11.44 | 15.47 | 95% CI | Beta |
 Diarrhea | 3.19 | 0 | 2.15 | 4.22 | 95% CI | Beta |
Utility | Â | |||||
 DFS | 0.80 | 0.73 | 0.87 | [48] | Beta | |
 Relapse | 0.73 | 0.66 | 0.8 | [48] | Beta | |
Disutility of grade 3/4 adverse events | Â | |||||
 Hand-foot syndrome | 0.12 | - | 0.096 | 0.144 |  ± 10% | Beta |
 Diarrhea | 0.10 | - | 0.08 | 0.12 |  ± 10% | Beta |
 Annual discount rate, % | 5 | 0 | 10 | - |  | |
 Transition probability, % | Model fit | - | - | 5% | Uniform |